David Lally, MD
Ophthalmology · Springfield, MANPI 1457686586
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $202,360 of the $328,327 with a category attached, or 61.6%. 24 manufacturers reported payments, led by Novartis at 32.5% of the total. Reporting peaked in 2019 at $105,900 and has fallen 63.8% since, to $38,319 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 308 payments — averaging $1066.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$107K
- Genentech USA, Inc.$66K
- Alimera Sciences, Inc.$31K
- Regeneron Healthcare Solutions, Inc.$24K
- AbbVie$22K
- Boehringer Ingelheim International GmbH$17K
- plus $63K from 18 others
Across 133 payments — averaging $31,678 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.2M
- Apellis Pharmaceuticals, Inc.$1.6M
- Genentech, Inc.$162K
- Eyepoint US, Inc.$109K
- AstraZeneca$74K
- Astellas Pharma Global Development$29K
- plus $62K from 4 others
What the payments were for
- Consulting fees$85,95826%
- Speaking & faculty fees$202,36062%
- Travel & lodging$30,5689%
- Food & beverage$9,1053%
- Other$3370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 66 | $106,603 |
| Genentech USA, Inc. | 54 | $65,673 |
| Alimera Sciences, Inc. | 42 | $31,105 |
| Regeneron Healthcare Solutions, Inc. | 21 | $23,597 |
| AbbVie(2 entities) | 41 | $21,603 |
| Boehringer Ingelheim International GmbH | 8 | $16,826 |
| Regeneron | 5 | $12,690 |
| Astellas Pharma Global Development | 7 | $10,815 |
| Eyepoint US, Inc. | 9 | $9,122 |
| Ocular Therapeutix, Inc. | 11 | $7,727 |
| Genentech, Inc. | 4 | $5,631 |
| Boehringer Ingelheim | 1 | $4,750 |
| F. Hoffmann-la Roche AG | 2 | $4,648 |
| Astellas Pharma US Inc | 12 | $3,186 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,113 |
| Apellis Pharmaceuticals, Inc. | 12 | $1,679 |
| Alcon | 2 | $356 |
| Coherus Oncology, Inc. | 3 | $93 |
| Harrow Eye, LLC | 1 | $32 |
| Biogen | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
| Notal Vision, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$328,327 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 172 | $7,133 |
| Difluprednate | 21 | $2,083 |
| Ofloxacin | 82 | $1,471 |
| Brimonidine Tartrate | 22 | $1,451 |
| Atropine Sulfate | 21 | $760 |
| Ketorolac Tromethamine | 31 | $604 |
| Latanoprost | 53 | $525 |
| Dorzolamide Hcl | 21 | $480 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $457 |
| Timolol Maleate | 18 | $271 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Springfield
- Tavish NandaSpringfield$26K
- Shilpa GulatiSpringfield$25K
- Rishi SinghBoston$1.7M
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
- Jeremy KievalLexington$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.